Erasca wins FDA Fast Track for ERAS-0015 in pancreatic cancer
Erasca says the FDA granted Fast Track designation to its Pan-RAS molecular glue ERAS-0015 for patients with metastatic pancreatic adenocarcinoma.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.